Ex-OpenAI executive raises $215 million for AI drug development startup

The company plans to use AI and automated laboratory equipment to speed up the process of creating and testing molecule variants after researchers identify promising drug candidates. Former OpenAI AI-for-science leader Kevin Weil is launching Warp Sciences with $215 million in funding to automate a key stage of drug development using artificial intelligence. The startup’s financing was led by Lightspeed Venture Partners, with IVP, Premji Invest and Lux Capital also participating. The round values Warp at $865 million after the investment, and its angel investors include executives and founders from OpenAI, Coinbase , Palantir and LinkedIn. Warp focuses on the process of producing and testing hundreds or thousands of variants of a promising molecule to improve its potential effectiveness and limit harmful side effects.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to Crypto Briefing.